SK Biopharmaceuticals Q3 Operating Profit Tops 100 Billion Won on U.S. Sales
SK Biopharmaceuticals’ corporate identity. SK Biopharmaceuticals (326030) posted third-quarter operating profit above 100 billion won, driven by expanding…
#EuropeSays #Korea #KR #SK #Cenobamate #epilepsydrug #operatingprofit #SKBiopharmaceuticals #SKGroup #third-quarterearnings #U.S.prescriptions #Xcopri
https://www.europesays.com/korea/217113/